Drug Topics
MAY 2, 2024
The current study highlights the potential benefit of incorporating continuous glucose monitor (CGM) data into eye care assessments for patients with type 1 diabetes (T1D).
Pharmacy Times
MAY 2, 2024
The vice president of pharmacy operations at American Oncology Network says that pharmacists can contribute by educating patients and offering resources for support and treatment adherence.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
MAY 2, 2024
A review found that many guidelines that recommended pharmacogenetic testing were inconsistent between clinical associations.
STAT
MAY 2, 2024
When male Sumatran orangutans let out a long call, they’re usually trying to grab female attention. But the sounds — a booming blend of roars and grunts — can end up attracting unwanted attention from other males, too. Things can get tense. Which is likely how Rakus, an adult male orangutan frequently seen in Gunung Leuser National Park in South Aceh, Indonesia, acquired a face wound in June 2022.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Fierce Healthcare
MAY 2, 2024
Google and DeepMind released an open access paper on their newest artificial intelligence tools intended for use in hea | Results released by Google on Med-Gemini's performance show that it outperforms existing AI/ML including GPT-4 on over a dozen industry benchmarks.
STAT
MAY 2, 2024
Another upload of genetic sequence data from the H5N1 bird flu outbreak in dairy cattle has exacerbated the scientific community’s frustration with the U.S. Department of Agriculture after the agency again failed to include basic information needed to track how the virus is changing as it spreads. Like a large tranche of sequences that the USDA uploaded to a public database on April 21, this week’s data dump did not include information about where and when the sequenced samples wer
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
MAY 2, 2024
It’s no secret that a lucky few seem to glide into old age, the years settling gracefully on their bodies, while others appear to have been dragged through time tied to a metaphorical garbage truck. Biologists have been developing numerous ways to measure the rate an individual ages — often called an accelerated or decelerated “biological age” — and trying to translate it into a heightened or reduced risk of the morbidity and mortality that comes with aging.
Pharmacy Times
MAY 2, 2024
Novo Nordisk and Eli Lilly have spoken out against the use of their GLP-1 medications for cosmetic weight loss, emphasizing the proper use of their medications.
STAT
MAY 2, 2024
If, after reading the latest recommendation on breast cancer screening by the United States Preventive Services Task Force (USPSTF), you feel like your head is spinning, that’s understandable. The task force’s newest advice , which gives a “B” grade in favor of routine mammograms for women in their 40s, reverses its 2016 statement saying the test should be optional for such women.
Pharmacy Times
MAY 2, 2024
The screenings should be conducted every other year, beginning at age 40 and continuing through age 74, according to the new recommendation.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Fierce Healthcare
MAY 2, 2024
Retail pharmacy giant Walgreens inked another partnership to recruit participants for research as it continues to build out its clinical trials business. | Walgreens has signed more than 35 clinical trial contracts with drugmakers including Freenome and Prothena. The aim is to optimize recruitment and make clinical trials more accessible, inclusive and equitable, the companies said.
pharmaphorum
MAY 2, 2024
Security and privacy within biotech are critical points of consideration and discussion as the industry continues to innovate at speed, and it is such aspects that are central to today’s podcast with Zach Powers, chief information security officer at Benchling, the R&D cloud platform for the biotech industry.
STAT
MAY 2, 2024
Families in America should never have to scrounge for baby formula. The United States needs a diverse and resilient supply of infant formula. Boosting the ability of smaller companies to compete in this market against the three large formula makers — Abbott, Mead Johnson, and Nestlé Gerber — could help make shortages a thing of the past.
Fierce Healthcare
MAY 2, 2024
The Cigna Group posted a $277 million loss in Q1 on the back of investment losses, according to its earnings report released Thursday. | The Cigna Group posted a $277 million loss in Q1 on the back of investment losses, according to its earnings report released Thursday.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Topics
MAY 2, 2024
A siloed approach to care can worsen patient outcomes, but collaboration between one health system specialty pharmacy and a manufacturer led to better patient care.
Fierce Healthcare
MAY 2, 2024
Hospitals’ margins and revenues took a slight dip in March, though it wasn’t enough to sour what has been a strong quarter for the sector. | Revenues, volumes and margins pulled back from February to March, with the strongest decline seen among outpatient settings. Sectorwide reports and recent earnings suggest that the sector is still well ahead of 2023.
Drug Topics
MAY 2, 2024
A recent bill introduced to Congress is intended to prevent product hopping, a practice that extends exclusivity and hinders the adoption of biosimilar therapies.
European Pharmaceutical Review
MAY 2, 2024
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a policy paper on its strategic approach to artificial intelligence (AI). It summarises the MHRA’s view on the UK government’s white paper on AI regulation published in 2023. Following publication of this white paper, the government requested that the MHRA outline the steps the agency is working on in relation to its expectations.
Drug Topics
MAY 2, 2024
The rise of weight-loss drugs has overtaken the US prescription drug market and significantly increased spending from 2022 to 2023.
STAT
MAY 2, 2024
Novartis already produces the leading drug in the radiopharmaceutical field. Now, it is devoting even more attention to these cancer treatments with a new acquisition. Novartis is paying $1 billion upfront and up to an additional $750 million if certain milestones are met to acquire startup Mariana Oncology, the latter company announced Thursday.
pharmaphorum
MAY 2, 2024
The updated ICH E6(R3) Good Clinical Practice guidelines are here - discover what's changed and how clinical trials will need to adapt. This in-depth post unravels the key impacts of E6(R3).
STAT
MAY 2, 2024
In a boost for Gilead Sciences, the California Supreme Court agreed to review a contentious legal theory that thousands of HIV patients have used in a closely watched case to argue drugmakers can be held negligent for failing to develop a medicine. Earlier this year, a state appeals court ruled the company could be held liable for halting further development of an HIV medicine that was safer than an HIV drug it was already selling.
Drug Topics
MAY 2, 2024
Distributors can help manufacturers create patient access programs that reduce costs, copays, and co-insurance.
pharmaphorum
MAY 2, 2024
Pursue your passion for science with a rewarding career in life sciences. Learn how a job in biology, biotech, or health sciences offers intellectual stimulation and the chance to improve lives.
Pharmacy Times
MAY 2, 2024
This class of drugs, including semaglutide, liraglutide, and tirzepatide, is used to treat type 2 diabetes and obesity.
STAT
MAY 2, 2024
Amgen said Thursday that it will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate that’s seen as a potential competitor to Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The injectable drug, called MariTide, is in a Phase 2 trial for obesity, and Chief Executive Bob Bradway said on an earnings call that “we are very encouraged with the results” from an interim analysis of that trial.
Drug Topics
MAY 2, 2024
Addressing requirements around FDA interchangeability designations can increase the adoption of biosimilar substitutions at the pharmacy level.
STAT
MAY 2, 2024
Transcarent, the fast-moving company helmed by health tech investor and former Livongo CEO Glen Tullman, today announced $126 million in Series D funding valuing the company at $2.2 billion. The investment round was led by venture capital giant General Catalyst and 7wireVentures, where Tullman is a managing partner. Transcarent will use the funding to support development of artificial intelligence capabilities across the enterprise, growing its business, and pursuing acquisitions, Tullman told S
Pharmaceutical Technology
MAY 2, 2024
From Merck & Co to Sanofi, Pharmaceutical Technology lists the leading pharmaceutical companies spending the most on R&D in 2023.
STAT
MAY 2, 2024
Novo Nordisk defended the prices of its blockbuster diabetes and obesity drugs Ozempic and Wegovy amid a Senate probe into what the company charges. Speaking on an earnings call Thursday, CEO Lars Fruergaard Jørgensen said the company launched the treatments at similar prices to earlier generations in the drug class, despite their having greater efficacy, making them “an attractive value proposition.
Fierce Healthcare
MAY 2, 2024
Alignment Healthcare boosted its health plan membership and is now projecting a higher full-year growth range, the insurtech announced ahead of its first-quarter earnings call. | Alignment Healthcare is growing its Medicare Advantage membership but shrinking its maximum adjusted EBITDA, the company announced ahead of its first quarter earnings call.
Drug Topics
MAY 2, 2024
Collaboration between health system specialty pharmacies and manufacturers can benefit patients in the long run.
European Pharmaceutical Review
MAY 2, 2024
Recent developments in the biologic therapies sector include the authorisation of Pyzchiva ® (biosimilar ustekinumab) by the European Commission, and promising 12-month data for Roche’s subcutaneous injection of OCREVUS ® (ocrelizumab) for relapsing or primary progressive multiple sclerosis. The biologics market is expected to continue its fast growth despite the slowdown in funding observed in the past year.
The Checkup by Singlecare
MAY 2, 2024
Dextroamphetamine/amphetamine ( Adderall and Adderall XR ) are prescription drugs that are primarily used to treat health conditions such as attention deficit hyperactivity disorder (ADHD) and narcolepsy. However, they are sometimes misused when people take higher than prescribed doses, which may lead to addiction to their effects , such as increased focus and extra energy.
Expert insights. Personalized for you.
220 
Let's personalize your content